BioLife Solutions, Inc. (BLFS) is a Healthcare stock trading at $36.96 (as of 2026-08-20), with a market capitalization of $1.81B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
BioLife Solutions develops and supplies bioproduction tools and services for cell and gene therapy, including biopreservation media (HypoThermosol FRS, CryoStor), thawing systems (ThawSTAR), and related bio storage and processing offerings, sold for use in research and commercial manufacturing.
The profit engine is adoption, its scale of revenue depends on how many cell and gene therapy programs and approved therapies embed its biopreservation media products and use its processing and storage platforms.
| CellProcPlatform | $0.0B |
| FreezersThaw | $0.0B |
| BiopreservationMedia | $0.0B |
| BioStorageServices | $0.0B |
Business quality (Weak): Clear linkage between business and operating KPIs (therapies embedding biopreservation media and platform revenue), but reported quarter revenue is extremely small in the provided data, limiting visibility into trend and cost leverage.
| Price | $36.96 |
| Market Cap | $1.81B |
| Price / Book | 4.85 |
| Price / Sales | 18.10 |
| FCF Yield | -0.0% |
| DCF Value (model) | $1.70 |
| DCF Upside vs Price | -95.4% |
| Revenue (TTM) | $96.21M |
| Net Margin | -4.8% |
| Revenue Growth (YoY) | 14.9% |
| EPS Growth (YoY) | -300.0% |
| FCF Growth (YoY) | -142.4% |
| Altman Z-Score | 31.16 (safe) |
| Piotroski F-Score | 6/9 (moderate) |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Medical Equipment) | 32.9 |
| Top Institutional Holder | T. Rowe Price Investment Management, Inc. ($124.14M) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 3 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | Roderick de Greef |
| Employees | 159 |
| Country | US |
| IPO Date | 1989-11-22 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.